Other
Relapsed or Refractory
10
Pipeline Programs↗
54
Active Trials↗
44
Companies Involved↗
Relapsed or Refractory is an early-stage landscape with 10 programs across 44 companies. The most active players are Kyowa Kirin Co., Ltd., Boehringer Ingelheim, Hebei Senlang Biotechnology Inc., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 110
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
183
clinical trials
Completed61 · 33%
Recruiting39 · 21%
Unknown status30 · 16%
Terminated27 · 15%
Active, not recruiting10 · 5%
Withdrawn8 · 4%
Other8 · 4%
Clinical Trials
Trial Activity
183 trials
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Recruiting·—·Phase 1·NCT05981209·27 enrolled
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
Recruiting·—·Phase 2·NCT04763616·37 enrolled
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Recruiting·—·Phase 2·NCT06316960·50 enrolled
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)